Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intellect Neurosciences has filed two US and one international patent application for passive and active immunotherapy approaches targeting abnormal forms of tau protein which causes death of nerve cells in Alzheimer's disease.
Subscribe to our email newsletter
Intellect’s new approach specifically targets neoepitopes that are formed following cleavage of intact tau protein by executioner caspases.
The pathological process is stimulated by an accumulation of amyloid beta in the brain of Alzheimer’s patients.
Intellect’s approach uses antibodies to clear the more toxic form, without risk of interfering with the functions of normal intact tau protein.
Intellect chairman and CEO Daniel Chain said they are encouraged by two studies results suggesting that tau may cause Alzheimer’s disease to spread through the brain.